2543 Weekly cabazitaxel in “unfit” metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial
Fernandez Parra, E.M., Ochoa, M., Castellano, D., Munielo, L., Juan, M.J., Perez Valderrama, B., Mellado, B., Fernandez Calvo, O., Anido, U., Domenech, M., Hernando, S., Arranz, J.A., Caballero, C., CVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31362-4
Date:
September, 2015
File:
PDF, 60 KB
english, 2015